MX2025010805A - Combinación de conjugado anticuerpo-fármaco anti-cdh6 e inhibidor de vegf - Google Patents

Combinación de conjugado anticuerpo-fármaco anti-cdh6 e inhibidor de vegf

Info

Publication number
MX2025010805A
MX2025010805A MX2025010805A MX2025010805A MX2025010805A MX 2025010805 A MX2025010805 A MX 2025010805A MX 2025010805 A MX2025010805 A MX 2025010805A MX 2025010805 A MX2025010805 A MX 2025010805A MX 2025010805 A MX2025010805 A MX 2025010805A
Authority
MX
Mexico
Prior art keywords
antibody
combination
drug conjugate
vegf inhibitor
cdh6 antibody
Prior art date
Application number
MX2025010805A
Other languages
English (en)
Spanish (es)
Inventor
Shotaro NAGASE
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2025010805A publication Critical patent/MX2025010805A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2025010805A 2023-03-14 2025-09-12 Combinación de conjugado anticuerpo-fármaco anti-cdh6 e inhibidor de vegf MX2025010805A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023039600 2023-03-14
PCT/JP2024/009716 WO2024190815A1 (ja) 2023-03-14 2024-03-13 抗cdh6抗体-薬物コンジュゲートとvegf阻害剤の組み合わせ

Publications (1)

Publication Number Publication Date
MX2025010805A true MX2025010805A (es) 2025-11-03

Family

ID=92755258

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025010805A MX2025010805A (es) 2023-03-14 2025-09-12 Combinación de conjugado anticuerpo-fármaco anti-cdh6 e inhibidor de vegf

Country Status (7)

Country Link
JP (1) JPWO2024190815A1 (enExample)
KR (1) KR20250170141A (enExample)
CN (1) CN120813389A (enExample)
AU (1) AU2024236246A1 (enExample)
MX (1) MX2025010805A (enExample)
TW (1) TW202444423A (enExample)
WO (1) WO2024190815A1 (enExample)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
EP2001358B1 (en) 2006-03-27 2016-07-13 University Of Maryland, Baltimore Glycoprotein synthesis and remodeling by enzymatic transglycosylation
EP2812442B9 (en) 2012-02-10 2023-02-15 University of Maryland, Baltimore Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
CN104755494B (zh) 2012-10-11 2018-09-07 第一三共株式会社 抗体-药物偶联物
HRP20190056T1 (hr) 2013-12-25 2019-02-22 Daiichi Sankyo Company, Limited Konjugat anti-trop2 antitijelo-lijek
SMT202500030T1 (it) 2014-01-31 2025-03-12 Daiichi Sankyo Co Ltd Coniugato anticorpo anti-her2-farmaco
DK3129063T3 (da) 2014-04-10 2021-04-06 Daiichi Sankyo Co Ltd Anti-her3-antistof-lægemiddelkonjugat
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
TW202532101A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體-藥物結合物及其用途
US11945882B2 (en) 2017-08-31 2024-04-02 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
EP3834843A4 (en) * 2018-08-06 2022-05-11 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR
EA202191641A1 (ru) * 2018-12-11 2021-09-13 Дайити Санкио Компани, Лимитед Комбинация конъюгата антитело-лекарственное средство с ингибитором parp
BR112021011894A2 (pt) * 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
KR20220152318A (ko) * 2020-03-12 2022-11-15 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4444360A1 (en) 2021-12-10 2024-10-16 Multitude Therapeutics Inc. Anti-cdh6 antibodies and antibody-drug conjugates thereof
WO2023102875A1 (en) 2021-12-10 2023-06-15 Multitude Therapeutics Inc. Anti-cdh6 antibody drug conjugate

Also Published As

Publication number Publication date
TW202444423A (zh) 2024-11-16
CN120813389A (zh) 2025-10-17
JPWO2024190815A1 (enExample) 2024-09-19
AU2024236246A1 (en) 2025-10-30
WO2024190815A1 (ja) 2024-09-19
KR20250170141A (ko) 2025-12-04

Similar Documents

Publication Publication Date Title
BR112021011119A2 (pt) Composição farmacêutica
MX2020012997A (es) Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso.
BR112023002417A2 (pt) Conjugado de anticorpo e fármaco
PH12021552831A1 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
MY199140A (en) Bifunctional proteins combining checkpoint blockade for targeted therapy
DE602004027888D1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihr
MX2021010003A (es) Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
MX2022016375A (es) Combinación de conjugado de anticuerpo-fármaco e inhibidor de la cinasa relacionada con ataxia telangiectasia y rad3 (atr).
SA523442921B1 (ar) جزيئات ربط علاجية
ZA202103719B (en) Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
ZA202305073B (en) Combination of antibody-drug conjugate and parp1 selective inhibitor
PE20221459A1 (es) Conjugados anticuerpo-farmaco dirigido a claudina 18.2
WO2020123836A9 (en) Herboxidiene antibody-drug conjugates and methods of use
MX2025005811A (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
MX2025006057A (es) Conjugados anticuerpo-farmaco anti-cea y metodos de uso
MX2024008000A (es) Combinacion de conjugado de anticuerpo-farmaco e inhibidor de cinasa relacionada con ataxia telangiectasia y rad3 (atr).
MX2025010805A (es) Combinación de conjugado anticuerpo-fármaco anti-cdh6 e inhibidor de vegf
UY38265A (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
MX2020010110A (es) Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.
MX2024007035A (es) Anticuerpos anti-cdh6 y conjugados anticuerpo-farmaco de los mismos.
MX2025007664A (es) Conjugados de anticuerpos farmacos b7h3
MX2025011453A (es) Combinacion de conjugado anticuerpo-farmaco anti-cdh6 e inhibidor de hif-2\03b1
MX2023008285A (es) Conjugado de anticuerpo anti-dll3-farmaco.